Table 2. Retrospective studies assessing the effect of metastectomy in patients with metastatic mucinous adenocarcinoma.
| Author | Year | Region | Period | Patients | Primary | S/M | Metastectomy | R0 | mOS, months |
|---|---|---|---|---|---|---|---|---|---|
| Rayson et al. (5) | 2000 | Canada | 1984–1998 | 38 | Colorectal | M 27, S 11 | 38 (100%) | R0 19/38 (50%) | 20 |
| Kim et al. (6) | 2001 | South Korea | 1987–1996 | 34 | Gastric | M 34 | 22/34 (65%) | 15/22 (68%)* | 7.7 |
| Cheong et al. (7) | 2004 | South Korea | 1987–2000 | 34 | Gastric | M 34 | 34 (100%) | R0 18/34 (53%) | 11 |
| Cheong et al. (8) | 2004 | South Korea | 1987–1998 | 54 | Gastric | M 54 | 33/54 (61%) | <1 cm 31/33 (94%) | 9 |
| McCormick et al. (9) | 2007 | USA | 1980–2005 | 39 | Colorectal | M 12, S 28 | 39 (100%) | <1 cm 29/39 (73%) | 30 |
| Jiang et al. (10) | 2009 | China | 1997–2003 | 54 | Gastric 26; colorectal 23; other 5 | M 41, S 13 | 54 (100%) | R0 32/54 (59%) | 17.8 |
| Tan et al. (11) | 2010 | Singapore | 1992–2004 | 25 | Colorectal | S 16, M 9 | 25 (100%) | Not recorded | 16.5 |
| Kim et al. (12) | 2010 | South Korea | 1994–2006 | 158 | Gastric 73; colon 61; other 13 | M 71, S 87 | 158 (100%) | <2 cm 93/158 (59%) | 15 |
| Ojo et al. (13) | 2011 | USA | 1994–2010 | 26 | Colorectal | M 4, S 22 | 25/26 | R0 8/26 (31%) | 27.5 |
| Jun et al. (14) | 2011 | South Korea | 1981–2008 | 22 | Gastric | M 22 | 22 (100%) | R0 16/22 (76%) | 18.8 |
| Wu et al. (15) | 2013 | China | 2000–2010 | 62 | Gastric | M 62 | 62 (100%) | PCI <16 after CRS14/32 (44%) | – |
| Lu et al. (3) | 2012 | Taiwan | 2000–2010 | 85 | Gastric | S 45, M 40 | 35 (41%) | Not recorded | 9 |
| Peng et al. (16) | 2013 | China | 1998–2011 | 133 | Gastric | S 69, M 64 | 133 (100%) | R0 83/133 (62%) | 16 |
| Cho et al. (17) | 2015 | South Korea | 2004–2012 | 216 | Gastric | S 84, M 132 | 107 (50%) | R0 41/107 (38%) | – |
| Wu et al. (18) | 2015 | China | 1990–2010 | 128 | Gastric 41; colorectal 58; other 21; unknown 8 | S 36, M 92 | 114 (89%) | Not recorded | 16 |
| Rosa et al. (2) | 2015 | Italy | 1990–2012 | 63 | Gastric | M 33, S 30 | 53 (84%) | R0 33/53 (62%) | 23 |
| Brieau et al. (19) | 2016 | France | 2001–2014 | 35 | Gastric | S 21, M 14 | 17 (49%) | Not recorded | 15.5 |
| Xu et al. (20) | 2017 | China | 1994–2013 | 57 | Colorectal | S 21, M 36 | 57 (100%) | R0 26/57 (46%) | 35 |
| Yu et al. (21) | 2017 | China | 2005–2014 | 152 | Gastric | M 59, S 92 | 89 (59%) | R0 57/90 (63%) | – |
| Ganesh et al. (22) | 2017 | USA | 1999–2015 | 195 | Colorectal | M 100, S 85 | 195 (100%) | R0 114/195 (58%) | 23 |
| Yan et al. (23) | 2018 | China | 2004–2015 | 103 | Gastric | S 103 | 54 (52%) | R0 32/54 (59%) | 15.8 |
| Ma et al. (24) | 2019 | China | 2006–2016 | 182 | Gastric | S 94, M 88 | 128 (70%) | R0 60/128 (47%) | – |
| Lin et al. (25) | 2022 | China | 2011–2021 | 130 | Gastric | S 82, M 48 | 88 (68%) | Not recorded | 13 |
| Fang et al. (26) | 2023 | China | 2011–2020 | 92 | Gastric | S 92 | 46 (50%) | R0 26/46 (56%) | 14 |
| Ostowari et al. (27) | 2024 | USA | 2012–2021 | 45 | Colorectal | S 45 | 43 (96%) | Not recorded | 50.3 |
| Bildersheim et al. (28) | 2024 | Canada | 2014 | 26 | Colorectal | S 5, M 21 | 10 (39%) | Not recorded | 30.4 |
*, no gross residual disease. S, synchronous; M, metachronous; R0, removal of all macroscopic disease; mOS, medium overall survival; PCI, Peritoneal Cancer Index; CRS, cytoreductive surgery.